Compare · CDXC vs PM
CDXC vs PM
Side-by-side comparison of ChromaDex Corporation (CDXC) and Philip Morris International Inc (PM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDXC and PM operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- PM is the larger of the two at $297.41B, about 1681.5x CDXC ($176.9M).
- PM has hit the wire 5 times in the past 4 weeks while CDXC has been quiet.
- PM has more recent analyst coverage (25 ratings vs 5 for CDXC).
- Company
- ChromaDex Corporation
- Philip Morris International Inc
- Price
- $7.87-0.76%
- $190.61-0.74%
- Market cap
- $176.9M
- $297.41B
- 1M return
- -
- +7.30%
- 1Y return
- -
- +16.96%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 5
- Recent ratings
- 5
- 25
ChromaDex Corporation
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Philip Morris International Inc
Philip Morris International Inc., through its subsidiaries, manufactures and sells cigarettes, other nicotine-containing products, smoke-free products, and related electronic devices and accessories. The company offers IQOS smoke-free products, including heated tobacco and nicotine-containing vapor products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, and Parliament HeatSticks brands, as well as under the Fiit and Miix licensed brands. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. It markets and sells its products in the European Union, Eastern Europe, the Middle East, Africa, South and Southeast Asia, East Asia, Australia, Latin America, and Canada. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.
Latest CDXC
- ChromaDex Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
- ChromaDex to Present at the 37th Annual Roth Conference
- SVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)
- ChromaDex Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
- SEC Form 10-K filed by ChromaDex Corporation
- SEC Form 4 filed by Chief Executive Officer Fried Robert N
- ChromaDex Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025
Latest PM
- SEC Form 10-Q filed by Philip Morris International Inc
- BTIG Research initiated coverage on Philip Morris International with a new price target
- Philip Morris International Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Philip Morris International Reports 2026 Second-Quarter & First Six-Months Results and Updates 2026 Full-Year Adjusted Diluted EPS Forecast for Currency Only;
- Philip Morris International to Host Webcast of 2026 Second-Quarter and First Six-Months Results
- Philip Morris International Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- PMI U.S. Unveils the ZYN America250 Art Series, Bringing Modern Culture to Limited-Edition Cases
- FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products
- Americans Are Losing Patience with Innovation That Doesn't Make Life Better, New Poll from PMI U.S. Finds
- Philip Morris International Inc filed SEC Form 8-K: Other Events